Innovus Pharma Receives Approval from Amazon® to Expand its Amazon® Stores to Europe Covering the United Kingdom, France, Germany, Spain and Italy

SAN DIEGO--()--Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced the approval from Amazon® for the expansion of its Amazon® stores to five European countries namely the United Kingdom, France, Germany, Spain and Italy. The additional store will increase the Company’s European presence and help Innovus Pharma’s customers access its products in English, French, German, Spanish and Italian. The Company expects to launch its European stores in the third quarter of 2018.

The Company anticipates that Amazon® stores’ sales will track to a $3 million annual run-rate and to a $5 million annual run-rate for all of its e-commerce site sales by the end of the year.

“We are delighted with the approval of our European Amazon® stores covering the United Kingdom, France, Germany, Spain and Italy,” said Dr. Bassam Damaj, the President and Chief Executive Officer of Innovus Pharma. “This expansion of our Amazon® sales to Europe through Amazon’s FBA shipping is a major step to globalize our direct sales without the need to continuously depend on finding local partners. The European expansion of our Amazon® stores follows the successful launches of our stores in the United States, Canada and Mexico.”

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.

For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; www.apeaz.com; and www.diabasens.com.

Innovus Pharma's Forward-Looking Safe Harbor:

Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, projected revenues from the sale of its products in Europe, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

Contacts

Innovus Pharma Investor Relations
Randy Berholtz, +1 858 249 7865
ir@innovuspharma.com

Contacts

Innovus Pharma Investor Relations
Randy Berholtz, +1 858 249 7865
ir@innovuspharma.com